Westlake Village BioPartners makes big bet on gene therapy with Capsida
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen planning apartments on its land in Thousand Oaks
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Arcutis shares down after earnings report
Westlake Village-based Arcutis Biotherapeutics suffered a net loss in the first quarter of fiscal year 2021, but continues to hold a strong financial position with $446.5 million in assets. According to earnings released May 4, Arcutis lost $36 million in the first quarter, or 76 cents per share, compared to a loss of $28 million, Read More →
Read More →Atara beats estimates with loss in Q1
Atara Biotherapeutics had a net loss of $78.2 million in the first quarter of fiscal year 2021, slightly higher compared than same quarter a year earlier, when the company had a loss of $73.5 million. Despite this, Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Read More →
Read More →Thousand Oaks biotech firm closes $140M funding round
Capsida Biotherapeutics, a biotechnology startup based in Thousand Oaks, announced April 29 that it is emerging from “stealth mode” with a $140 million funding round led by Westlake Village BioPartners and Versant Ventures. The Series A round includes $50 million from Westlake Village BioPartners, a venture capital firm in Thousand Oaks focused on biotech startups Read More →
Read More →Amgen stock tumbles after earnings report
Editor’s note: This article was updated at 8:35 a.m. on April 28 with up-to-date information on Amgen’s stock price. Amgen’s shares fell nearly 8% following the company’s April 27 release of its first quarter 2021 earnings, which saw a decline in both revenue and net income compared to a year earlier. Amgen is headquartered in Read More →
Read More →Amgen announces $721M acquisition
Amgen reported its second major acquisition of the month, as the Thousand Oaks-based firm announced March 30 that it will acquire Rodeo Therapeutics Corporation, a privately held biotech company based in Seattle. The deal is worth more than $700 million, $55 million of which will be paid upfront, with up to $666 million more in Read More →
Read More →
